Bimagrumab

Drug Profile

Bimagrumab

Alternative Names: BYM-338

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Type II-B activin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cachexia; Muscular atrophy; Type 2 diabetes mellitus
  • Discontinued Inclusion body myositis

Most Recent Events

  • 27 Jan 2017 Discontinued - Phase-III for Inclusion body myositis (In the elderly, In adults) in Belgium, Denmark, Italy, Japan, Netherlands, United Kingdom, France, Germany, Poland, Switzerland, Australia, USA (IV) (Novartis 20-F filed in 2017)
  • 12 Jan 2017 Phase-II clinical trials in Type-2 diabetes mellitus in USA (IV) (NCT03005288)
  • 28 Dec 2016 Novartis plans a phase II trial for Type-2 diabetes mellitus in USA (NCT03005288)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top